# GoodRx Holdings, Inc. (GDRX)

> Source: Nexqual · https://nexqual.com/GDRX · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, GoodRx Holdings, Inc. (GDRX), nexqual.com/GDRX" · informational, not investment advice.

**Price:** USD 3.62 (+1.40% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 3.57 · day 3.55–3.64 · 52w 1.77–4.05 · market cap $1.23B · NMS

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $785M, net income $16.2M (2.1% margin), free cash flow $197M (SEC filings).
- Valuation: P/E 76.0x (avg 71.5x at the last 2 fiscal year-ends), EV/EBITDA 8.7x, net debt $190M.
- Earnings quality: non-operating income -$33.5M vs operating income $74.9M over the last four quarters; P/E excluding non-operating income ≈32.5x (estimate: non-operating income taxed at the company's 35% effective rate).
- Insider open-market sales, last ~7 months: 2 Form 4 filings, $9.7M; 2 not under a Rule 10b5-1 plan ($9.7M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Hold (mean 2.93 on a 1–5 scale) (14 analysts), mean target USD 3.95 (range 2.65–5).
- Total return with dividends: 1Y -6.2% vs S&P 500 +14.9%; 5Y -92.3% vs S&P 500 +80.3%.
- Next earnings: 2026-11-03, EPS estimate USD 0.08, revenue estimate $202M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $745M | $767M | $750M | $792M | $797M | $785M |
| Operating income | $13.4M | $1.7M | -$27.0M | $65.8M | $87.5M | $74.9M |
| Net income | -$25.3M | -$32.8M | -$8.9M | $16.4M | $30.4M | $16.2M |
| EPS (diluted) | -$0.06 | -$0.08 | -$0.02 | $0.04 | $0.09 | — |
| Free cash flow | $174M | $143M | $137M | $183M | $164M | $197M |
| Operating margin | 1.8% | 0.2% | -3.6% | 8.3% | 11.0% | 9.5% |
| Net margin | -3.4% | -4.3% | -1.2% | 2.1% | 3.8% | 2.1% |
| Revenue growth | +35.4% | +2.8% | -2.1% | +5.6% | +0.6% | — |
| Cash + short-term investments | $941M | $757M | $672M | $448M | $262M | — |
| Total debt | $674M | $667M | $656M | $500M | $495M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/E 76.0x · P/E ex non-operating (est.) ≈32.5x · P/S 1.6x · EV/EBITDA 8.7x · EV/Sales 1.8x · P/FCF 6.3x · P/B 1.9x · FCF yield 15.96% · Earnings yield 1.32% · Buyback yield (TTM) 6.88% · Net debt $190M · EV $1.43B
P/E at fiscal year-ends: Dec 2025 31.8x, Dec 2024 111.3x.

## Insider sales (SEC Form 4, open-market, last ~7 months)
0 of 2 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-08-24…2026-08-26 | Francisco Partners Iv, L.P. |  | 1,567,044 | $5.5M | 100% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-08-19…2026-08-21 | Francisco Partners Iv, L.P. |  | 1,193,951 | $4.2M | 43.2% | No | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Hold (mean 2.93 on a 1–5 scale), 14 analysts; mean target USD 3.95 (low 2.65, high 5).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-21 | Barclays | Target raised | Underweight | $3 → $4 |
| 2026-08-13 | UBS | Target raised | Neutral | $2.5 → $3.75 |
| 2026-08-11 | Citigroup | Target raised | Buy | $4 → $5 |
| 2026-08-11 | TD Cowen | Target raised | Buy | $4 → $5 |
| 2026-08-07 | Wells Fargo | Target raised | Overweight | $3.5 → $5 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | -6.2% | -92.3% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -6.2% | -40.1% |
| Volatility (annualized) | 56.1% | 72.0% |
| Max drawdown | -52.7% (Oct 2025→Feb 2026) | -96.0% (Oct 2021→Feb 2026) |

## Peers (Health Information Services)
OMDA (Omada Health, Inc.) USD 18.98 -3.46% · TDOC (Teladoc Health, Inc.) USD 6.32 +0.32% · HSTM (HealthStream, Inc.) USD 34.59 +3.22% · CERT (Certara, Inc.) USD 10.09 -0.88% · OMCL (Omnicell, Inc.) USD 37.1 +2.09% · SDGR (Schrodinger, Inc.) USD 22.6 -5.44%

## More
Full page: https://nexqual.com/GDRX · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in GDRX's own 10-K filed 2026-02-26 (https://www.sec.gov/Archives/edgar/data/1809519/000180951926000031/gdrx-20251231.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Apple (AAPL) | "We rely on third-party platforms such as the Apple App Store and Google Play App Store, to distribute our platform" |
| Supplier | Alphabet (Google) (GOOGL) | "We rely on third-party platforms such as the Apple App Store and Google Play App Store, to distribute our platform" |
| Partner | Idea Men | "Partners, and Idea Men, LLC in accordance with our stockholders agreement." |

## Revenue by product line (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Prescription transactions revenue | $106.4M | 53.1% | -25.6% |
| Pharma Direct revenue | $61.6M | 30.8% | +76.2% |
| Subscription revenue | $28.5M | 14.2% | +39.3% |
| Other revenue | $3.9M | 1.9% | -15.0% |
| Total revenue | $200.4M | 100% | — |

## Customer concentration

Period ended 2025-06-30: 12% of revenue from unnamed direct customers (10-Q, filed 2026-08-05).

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $0.08 | $0.08 | -2.3% | $202.1M | 11 |
| Next quarter (ends 2026-12-31) | $0.08 | $0.08 | -5.1% | $202.1M | 11 |
| Current fiscal year (ends 2026-12-31) | $0.30 | $0.31 | -1.9% | $798.5M | 11 |
| Next fiscal year (ends 2027-12-31) | $0.35 | $0.36 | -1.7% | $836.2M | 11 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2027-01-15 (includes earnings 2026-11-03): ±38.9%; last 8 reports averaged ±10.3%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2027-01-15 | 84 | 94.0% | ±38.9% |
| 2027-04-16 | 175 | 97.2% | ±43.8% |